Effect of Drugs Used in the Treatment of Asthma on the Production of Eosinophil-Activating Factor by Monocytes
- 1 January 1988
- journal article
- research article
- Published by S. Karger AG in International Archives of Allergy and Immunology
- Vol. 85 (2) , 257-259
- https://doi.org/10.1159/000234513
Abstract
The cytotoxic activity of eosinophils, as measured by their ability to kill antibody-coated schistosomula of Schistosoma mansoni, is enhanced by a factor (eosinophil-activating factor, EAF) which is secreted by peripheral blood monocytes from certain moderately eosinophilic individuals. The secretion of this factor by monocytes is inhibited by methylprednisolone (1 μg/ml), beclomethasone (10 μg/ml) and theophylline (100 μg/ml), but not by sodium cromoglycate or salbutamol. Methylprednisolone, beclomethasone and theophylline do not inhibit either eosinophil cytotoxic activity or enhancement of eosinophil cytotoxic activity by EAF at these concentrations.Keywords
This publication has 5 references indexed in Scilit:
- A comparison of eosinophil-activating factor (EAF) with other monokines and lymphokinesEuropean Journal of Immunology, 1986
- Partial purification and biological properties of an eosinophil-activating factorEuropean Journal of Immunology, 1985
- Enhancement of human eosinophil-mediated killing of Schistosoma mansoni larvae by mononuclear cell products in vitro.The Journal of Experimental Medicine, 1983
- Comparison of Human Eosinophils from Normals and Patients with EosinophiliaJournal of Clinical Investigation, 1980
- A New Method for the Purification of Human Eosinophils and Neutrophils, and a Comparison of the Ability of These Cells to Damage Schistosomula of Schistosoma MansoniThe Journal of Immunology, 1979